The Efficacy And Safety Of Apatinib Treatment For Patients With Advanced Lung Cancer

Objective:The aim of our study was to assess the efficacy and safety of apatinib for the treatment of advanced lung cancer after the failure of second-line therapy.Methods:We retrospectively analyzed the data of 48 patients with advanced lung cancer after the failure of second-line therapy,according to the treatment of patients divided into the apatinib treatment group 25 cases and the simple chemotherapy group 23 cases.Follow-up was continued until disease progression or death.Statistical analysis relying on SPSS22.0 software.Thechi-square test was used to compare the clinical characteristics,short-termCurative effect and adverse events.Kaplan-Meier method and Cox regression model were used for progression freesurvival(PFS)analysis.Results:The median progression-free survival(mPFS)of apatinib group and chemotherapy group were 2.9 and 1.7 months,the difference was statistically significant(p<0.05).The objective responserate(ORR)was 28.0%and 13.0%in apatinib monotherapy group and chemotherapy alone group,respectively(p>0.05),and the disease control rate(DCR)were 88.0%and 52.2%respectively(p<0.05).The difference of DCR was statistically significant.Univariate analysis showed that ECOG and age were correlated with PFS(p<0.05)in the apatinib monotherapy group.While gender,pathological type,smoking history,disease course and the numbers of metastasese were not associated with patients' prognosis(p>0.05).The incidence of hypertension in the apatinib monotherapy group and chemotherapy alone group were 52.2%(13cases)and 4.3%(1case)respectively.The incidence of proteinuria in the apatinib group and chemotherapy group were 28.0%(7 cases)and 4.4%(1 case)respectively.The incidence ofgastrointestinal reaction in the apatinib group and chemotherapy group were 28.0%(7 cases)and 60.9%(14 cases)respectively.The differences were statisticallysignificant(p<0.05),and the incidence of other adverse events such as fatigue,hand-foot syndrome,myelosuppression and stomatitis of twogroups are not significantly different(p>0.05).Conclusion:Comparing to chemotherapy group,the apatinib group has a better control of disease and survival benefit for advanced lung cancer after the failure of second-line therapy,and its adverse events are tolerant.Apatinib may be a promising therapeutic drug for advanced lung cancer after the failure of second-line therapy.